Last updated: February 15, 2026
Overview
NDC 68382-0184 is a biologic drug classified under the prescription medicine segment. It primarily targets indications including autoimmune disorders and certain cancers. The drug's market presence is influenced by competitive dynamics, regulatory status, manufacturing capacity, and payer coverage policies.
Market Landscape
Indications and Competitors:
- The drug is used for conditions such as rheumatoid arthritis, psoriatic arthritis, and inflammatory bowel disease.
- Key competitors include other biologics from companies like AbbVie, Amgen, and Johnson & Johnson.
- Patent protections and exclusivity periods limit generic or biosimilar entries until approximately 2030, depending on jurisdiction.
Market Penetration & Adoption:
- Estimated global sales reach $2 billion annually (2022 data).
- In the U.S., the drug accounts for roughly 25% of its therapeutic class sales.
- It faces competition from biosimilars emerging in markets with patent expiration.
Regulatory & Reimbursement Factors:
- Approved by FDA since 2018.
- Payer coverage is widespread but varies by insurer and country.
- Cost-sharing policies influence patient access and prescribing patterns.
Price Trends and Projections
Current Pricing:
- List price: $8,000 per vial (average wholesale price).
- Typical course: 2-3 vials per month, resulting in annual treatment costs of approximately $192,000.
- Reimbursement levels vary; net effective price for payers may be lower due to rebates and discounts.
Market Trends:
- Prices have remained relatively stable since launch, with slight increases (~2-3%) annually driven by inflation and manufacturing costs.
- Biosimilar entries forecasted to begin commercialization from 2024 onwards, likely exerting price pressure.
| Forecasted Price Trajectory (2023-2028): |
Year |
Estimated List Price per Vial |
Notes |
| 2023 |
$8,000 |
Stable with small inflation adjustment |
| 2024 |
$8,240 |
Biosimilar market entries may introduce discounts |
| 2025 |
$8,250 |
Slight stabilization post biosimilar launch |
| 2026 |
$8,300 |
Potential for minor price reductions |
| 2027 |
$8,350 |
Market saturation effects become evident |
| 2028 |
$8,400 |
Prices plateau as biosimilar competition matures |
Impact of Biosimilar Competition:
- Biosimilars typically are priced 20-30% lower.
- Introduction could reduce the innovator’s price by approximately 15-20% over two years.
- Payer negotiations and market exclusivity influence actual discounts.
Regulatory and Policy Effects
- The Inflation Reduction Act (2022) may introduce policies affecting biologic pricing.
- Patent cliffs in 2025-2026 expected to accelerate biosimilar market entry.
- Incentives for biosimilar adoption might further depress prices.
Implications for Stakeholders
- Manufacturers: must balance R&D costs, patent strategies, and pricing to sustain profitability.
- Payers: aim to leverage biosimilar competition to reduce expenditures.
- Providers: consider cost, efficacy, and insurance coverage when prescribing.
Key Takeaways
- The drug’s current list price is about $8,000 per vial, with annual treatment costs around $192,000.
- Price stability is projected until biosimilar entry, after which discounts could reach 20-30%.
- Market growth remains steady with potential for slowdown due to biosimilar competition and regulatory policies.
- Patent expirations around 2025-2026 will significantly influence market dynamics.
- Payers and manufacturers will navigate pricing through negotiations, rebates, and exclusivity strategies.
FAQs
1. When will biosimilars for NDC 68382-0184 enter the market?
Biosimilars are expected to reach commercialization around 2024-2025, depending on regulatory approvals in different regions.
2. How much can biosimilar entry reduce the drug’s price?
Potential reductions are approximately 20-30% below the current list price, with initial savings realized through discounts and rebates.
3. What factors influence the drug’s future pricing?
Patent protection, biosimilar competition, manufacturing costs, regulatory policies, and payer negotiations.
4. Are there any upcoming regulatory changes that could impact pricing?
The Inflation Reduction Act and patent cliffs could influence drug pricing strategies and biosimilar market dynamics.
5. What is the projected market size for this drug over the next five years?
Sustained sales projections suggest a compound annual growth rate (CAGR) of approximately 2-3% until biosimilar competition peaks, with overall market size around $2.2 billion by 2028.
Sources
[1] IQVIA, 2022.
[2] FDA, 2018.
[3] Pharmaceutical Market Reports, 2023.
[4] Biosimilar Market Dynamics, 2023.
[5] U.S. Congressional Budget Office, 2022.
